| Abstract | Hormonal therapy has an established place in the management of women with gynaecological malignancies, including first-line therapy for recurrent receptor-positive endometrial cancer and low-grade stromal sarcoma. There is no place for adjuvant hormonal treatment of these cancers after primary surgery. Primary treatment with either oral or intra-uterine progestagens to preserve fertility in younger women with endometrial carcinoma is effective in about 70% of cases. Response rates to tamoxifen in advanced/recurrent ovarian cancers approximates 10%. To the authors' knowledge, no studies that reasonably compare different progestagens, different routes of therapy, different doses and different hormonal preparations have been published. |
| Authors | Andrea Garrett, Michael A Quinn
(Affiliation: Mercy Hospital for Women, Heidelberg, Victoria 3084, Australia. AGarrett at mercy.com.au)
|
| Journal | Best practice & research. Clinical obstetrics & gynaecology
(Best Pract Res Clin Obstet Gynaecol)
Vol. 22
Issue 2
Pg. 407-21
(Apr 2008)
ISSN: 1521-6934 England |
| PMID | 17884734
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Antineoplastic Agents, Hormonal
- Aromatase Inhibitors
- Progestins
- Tamoxifen
|
| Topics |
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Aromatase Inhibitors
(therapeutic use)
- Endometrial Neoplasms
(drug therapy)
- Estrogen Replacement Therapy
- Female
- Genital Neoplasms, Female
(drug therapy)
- Humans
- Ovarian Neoplasms
(drug therapy)
- Progestins
(therapeutic use)
- Sarcoma, Endometrial Stromal
(drug therapy)
- Tamoxifen
(therapeutic use)
|
